Peptide Category Comparison: Glucagon Receptor Agonist vs. GLP-1 Analogs
Abstract: This analysis compares glucagon receptor agonists (GRAs) and GLP-1 analogs within the peptide therapeutics market. GRAs, primarily targeting metabolic disorders like type 2 diabetes and obesity, offer distinct mechanisms but face challenges in glycemic control and tolerability versus GLP-1 analogs, which dominate the market with superior safety profiles and cardiovascular benefits. Key differentiators include product composition (e.g., dual vs. single agonists), pharmacokinetic parameters, and manufacturing complexity. Market trends show a shift toward multi-target peptides, with leading brands (e.g., semaglutide, tirzepatide) driving growth. Selection criteria emphasize purity, stability, and regulatory certifications (e.g., GMP, USP). Logistics require cold-chain management. Industry data projects a CAGR exceeding 15% through 2030, underscoring the need for rigorous quality assessment in sourcing.